No-Cost Evaluation System

Posted: January 10th, 2008

Jovus announces a no-cost evaluation program for research creation, editing, compliance and publication for qualified firms...

Jovus offers the most comprehensive and cost-effective equity research system on the market today, and we welcome comparison to any system you may now have in place. Therefore we are pleased to announce a unique offer that will allow you to experience the versatility and power of our industry leading system at no cost to you and without obligation to purchase. Jovus is the choice of some of the largest, most respected research firms in the world. It will take your firm's research output products from authoring through publishing and distribution in record time, with better quality, less chance of error and at less expense. Our limited-time offer provides firms with as few as five publishing analysts access to Jovus demo software that features:

• No cost evaluation Period of up to 30 days
• No contracts or obligation to purchase at the conclusion of your evaluation
• No hidden fees

Ease-of-use and productivity benefits you will see first-hand include*:

Web-based, efficient workflow — your analysts can work from anywhere in the world.

Full MS Word integration - work in MS Word with or without an Internet connection.

Highest quality image rendering for charts, tables, etc. for impressive results.

Fully automated integration of market data and all required charts and disclosures.

One touch distribution to 3rd-party recipients (First Call, Reuters, Bloomberg, etc.)

Jovus Meets or Exceeds all FINRA, NYSE and IDA Research Regulations

Simply put, this is an open invitation to experience world-class software - as a live, full-production system or in parallel with your existing method of research production. Should you decide to discontinue use of the system at the end of your evaluation period, we will simply ask you to complete a brief questionnaire describing your experience in using our services.

What could be more direct or simple? For more information on how to qualify and subscribe for this offer, please call toll-free: (866) 955-6887 X-102.

We look forward to speaking with you.

* Select features such as actual distribution of research will be disabled for the trial period.